GALT Latest Report

Financial Performance

Based on the provided financial data, Galectin (stock code: GALT) recorded a revenue of -12428000 yuan in December 2024, a decrease of 2867000 yuan from -9561000 yuan in 2023, indicating a negative growth. This suggests a significant deterioration in the company's revenue, which may face operational difficulties. In addition, the increase in research and development expenses and interest expenses also exacerbated the company's financial pressure, and the deterioration of comprehensive income further reflected the poor overall financial situation.

Key Financial Data

1. Revenue Decline: The revenue in 2024 was -12428000 yuan, indicating a weakening of sales or market demand.

2. Increased R&D Expenses: The R&D expenses in 2024 were 11109000 yuan, an increase from 8228000 yuan in 2023, which failed to effectively convert into revenue and instead exacerbated the financial pressure.

3. Increased Interest Expenses: The interest expenses in 2024 were 1725000 yuan, a significant increase from 847000 yuan in 2023, further compressing the profit margin.

4. Deteriorated Comprehensive Income: The total comprehensive income in 2024 was -11967000 yuan, further deteriorated from -9997000 yuan in 2023, reflecting the overall deterioration of the financial situation.

Peer Comparison

1. Industry-wide Analysis: Companies in the biopharmaceutical industry often experience revenue fluctuations during the R&D stage, and are greatly affected by market demand and policy changes. The overall industry may exhibit revenue fluctuation characteristics, and paying attention to the performance of other companies in the industry can help understand Galectin's revenue changes.

2. Peer Evaluation Analysis: Galectin's revenue has been consistently negative, indicating its disadvantage in the market competition. Further analysis of the financial performance of peer companies is needed to assess Galectin's market position and future growth potential.

Conclusion

Galectin faces multiple financial pressures in 2024, including a significant decline in revenue, an increase in R&D expenses, and an increase in interest expenses. The deterioration of comprehensive income indicates the overall deterioration of the company's financial situation, which may affect its competitiveness and development prospects in the biopharmaceutical industry.

Opportunities

1. If future R&D results are converted into market products, it is expected to improve revenue levels.

2. The trend of industry integration may provide Galectin with opportunities to cooperate with other companies.

3. Policy support helps to promote innovation in the biopharmaceutical field, and Galectin can take advantage of this opportunity to adjust its strategy and market expansion.

Risks

1. Continuous negative revenue may lead to financing difficulties, affecting the company's operations.

2. R&D investment that fails to bring expected income may affect investor confidence.

3. Intensified market competition, with peer companies performing well, may result in further market share loss for Galectin.